key: cord-0820662-hdjm9iuh
authors: Buchheit, Kathleen M.; Hacker, Jonathan J.; Gakpo, Deborah H.; Mullur, Jyotsna; Sohail, Aaqib; Laidlaw, Tanya M.
title: Influence of daily aspirin therapy on ACE2 expression and function—implications for SARS‐CoV‐2 and patients with aspirin‐exacerbated respiratory disease
date: 2021-05-26
journal: Clin Exp Allergy
DOI: 10.1111/cea.13898
sha: e44b6c1ca835db73c92440ebb86e6e1899d4eb19
doc_id: 820662
cord_uid: hdjm9iuh

In March 2020, the French Minister of Health warned against the use of non-steroidal anti-inflammatory drugs (NSAIDs) like aspirin and ibuprofen, suggesting that their use might be associated with more severe disease presentation in patients with COVID-19.1 This advice was apparently based on unpublished anecdotal reports that patients who had been exposed to NSAIDs developed more severe symptoms of COVID-19.

In March 2020, the French Minister of Health warned against the use of non-steroidal anti-inflammatory drugs (NSAIDs) like aspirin and ibuprofen, suggesting that their use might be associated with more severe disease presentation in patients with COVID-19. 1 This advice was apparently based on unpublished anecdotal reports that patients who had been exposed to NSAIDs developed more severe symptoms of COVID-19. At the time, there was limited indirect data suggesting that NSAIDs may up-regulate angiotensin-converting enzyme 2 (ACE2) expression, 2 which is the target receptor for cell entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and some speculated that an NSAID-induced up-regulation of ACE2 could explain the French minister's observations. Though more recent clinical reports have not found any association between NSAID use and a more severe course of COVID-19, 3, 4 there is still remaining concern about possible mechanistic links between NSAID use and ACE2 expression. Specifically for our patients with aspirinexacerbated respiratory disease (AERD), for whom high-dose aspirin therapy is often an efficacious treatment to help reduce the regrowth of nasal polyps and decrease respiratory inflammation, 5 it is important that we are able to provide them with evidence-based management regarding the safety of their aspirin therapy during this pandemic.

SARS-CoV-2 cell entry requires ACE2, along with transmembrane serine protease 2 (TMPRSS2), to bind to host epithelial cells, and the highest expression of ACE2 is found in the secretory cells of nasal epithelium. [6] [7] [8] Nasal epithelial cells express both ACE2 and TMPRSS2 and their increased expression in the upper airway may allow for increased host susceptibility to infection. However, once SARS-CoV-2 binds to ACE2, receptor-mediated internalization leads to decreased ACE2 activity. ACE2 can generate the biologically active fragments Ang (1-9) and Ang (1-7), which block Angiotensin-II and inhibit ACE, so that the ACE2 axis negatively regulates ACE. 9

In patients with acute respiratory distress syndrome and lung injury, plasma Ang-I levels are significantly higher in non-survivors, whereas survival is associated with higher plasma Ang (1-9) and Ang (1) (2) (3) (4) (5) (6) (7) . This suggests that high ACE2 activity systemically is beneficial for survival of acute lung injury, 10 which has become a major cause of morbidity and mortality during this COVID-19 pandemic.

Therefore, although ACE2 expression in the nasal epithelium is a required entry point for viral infection, continued high levels of systemic ACE2 activity may paradoxically be beneficial post-infection.

Consequently, internalization of ACE2 during SARS-CoV-2 infection could reduce ACE2 activity that is important for survival. The host factors that regulate ACE2 expression and activity are not fully known and are missing pieces required to expand our understanding of the pathogenesis of this disease. The influence of aspirin on nasal ACE2 expression and the subsequent production of angiotensin peptides has never been studied. A single human study showed that plasma ACE2 levels were potentially higher in patients taking aspirin, suggesting a possible protective effect of NSAIDs. 2 In this study, we Two-sided Student's t test assessed paired differences before and after aspirin, and ANOVA assessed unpaired differences between baselines of the three patient groups. Analysis was performed using GraphPad Prism version 7.0d (GraphPad, La Jolla, CA).

Patient demographics are summarized in Table 1 . Plasma levels of ACE2, Ang-I, Ang-II, Ang(1-7) and Ang(1-9) were detectable in most samples (Figure 1 , A-F), though only Ang(1-7) was consistently detectable in nasal fluid (Figure 1, E) . There were no significant baseline differences in any angiotensin peptides across the three patient groups, nor were there significant aspirin-induced differences in asthmatic subjects. There were some AERD subjects with an aspirin-induced increase in plasma ACE2, but this was not statistically significant (1.79 ±1.21ng/mL to 5.87 ±3.27ng/mL, p=0.156).

ACE2 transcript was detectable in most nasal scraping samples, and TMPRSS2 was detectable in all samples. There was no significant aspirin-induced difference in either ACE2 or TMPRSS2 transcript expression (Figure 1 , G-H).

As patients with AERD are often treated with daily high-dose aspirin therapy, we aimed to understand the immunologic influence of daily aspirin on SARS-CoV-2 susceptibility. Eight weeks of daily aspirin treatment in patients with asthma or AERD did not significantly change nasal epithelial transcript expression of ACE2 or TMPRSS2 or alter levels of angiotensin-derived peptides potentially relevant to survival in acute respiratory distress syndrome. Furthermore, consistent with studies showing asthma is generally not a risk factor for severe COVID-19, our data show that asthmatic subjects did not have any difference in angiotensin-derived peptide levels compared with controls.

Although we are not able to extrapolate these results out for patients who are on aspirin for more than eight weeks, our data suggest that

• Daily aspirin does not change nasal expression of ACE2 or TMPRSS2 or alter levels of angiotensin-derived peptides in patients with AERD or aspirin-tolerant asthma, suggesting that its use is unlikely to increase risk of severe SARS-CoV-2 infection.

• Patients with AERD or aspirin-tolerant asthma do not have differences in plasma levels of angiotensin-derived peptides compared with non-asthmatic controls. 

Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study

Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: A Danish nationwide cohort study

Bar-Haim A, Youngster I. Ibuprofen use and clinical outcomes in COVID-19 patients

Aspirin desensitization vs biologics for patients with aspirin-exacerbated respiratory disease

Individual Variation of the SARS-CoV2 Receptor ACE2 Gene Expression and Regulation

SARS-CoV-2 Receptor ACE2 is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Enriched in Specific Cell Subsets Across Tissues

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Renin-angiotensin system in human coronavirus pathogenesis

Circulating angiotensin peptides levels in Acute Respiratory Distress Syndrome correlate with clinical outcomes: A pilot study